← Eichor
Study identifier: NCT05288205 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

Condition: KRAS P.G12C · Non-small Cell Lung Cancer · Colorectal Cancer  ·  Sponsor: Allist Pharmaceuticals, Inc.

PhasePhase 1/Phase 2
Planned participants240
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a multicenter, open-label phase 1/2a study consisting of two parts: dose escalation phase and dose expansion phase. The objective of the dose escalation phase is to evaluate the safety, tolerability and pharmacokinetics of JAB-21822 in combination with JAB-3312 in patients with advanced solid tumors harboring KRAS p.G12C mutation and to determine the RP2D for the combination therapy. In the dose expansion phase, preliminary efficacy and safety of the combination therapy at the RP2D will be further explored in patients with specific cancer harboring KRAS p.G12C mutation.

This description comes directly from the study's public registry record.

Talk to the study team

Shanghai Allist Pharmaceuticals Co., Ltd Shanghai Allist Pharmaceuticals Co., Ltd  ·  021-80423288  ·  zhenhua.gong@allist.com.cn

Always discuss trial participation with your own doctor first.

Locations (27)

The First Affiliated Hospital of USTC Anhui Provincial HospitalHefei, Anhui, ChinaNot Yet Recruiting
Pecking Union Medical College HospitalBeijing, Beijing Municipality, ChinaNot Yet Recruiting
Cancer Hospital Chinese Academy Of Medical SciencesBeijing, Beijing Municipality, ChinaRecruiting
Beijing Tiantan Hospital, Captal Medical UniversityBeijing, Beijing Municipality, ChinaNot Yet Recruiting
Beijing Cancer HospitalBeijing, Beijing Municipality, ChinaRecruiting
Peking University Third HospitalBeijing, Beijing Municipality, ChinaRecruiting
Beijing Chest Hospital, Capital Medical UniversityBeijing, Beijing Municipality, ChinaNot Yet Recruiting
Fujian cancer HospitalFuzhou, Fujian, ChinaNot Yet Recruiting
The First Affiliated Hospital Xiamen UniversityXiamen, Fujian, ChinaNot Yet Recruiting
The first Affiliated Hospital, Sun Yat-sen UniversityGuangzhou, Guangdong, ChinaNot Yet Recruiting
Zhujiang Hospital of Southem Medical UniversityGuangzhou, Guangdong, ChinaNot Yet Recruiting
Cancer Hospital Chinese Academy Of medical Sciences Shenzhen CenterShenzhen, Guangdong, ChinaNot Yet Recruiting

+ 15 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05288205